Copper drug restores memory and clears toxic Alzheimer's proteins, preclinical study finds

Article excerpt

A drug that delivers copper directly to the brain reduced toxic Alzheimer's proteins and restored long-term spatial memory in laboratory experiments at Monash University. The compound works by targeting the buildup of amyloid-beta and tau, the hallmark proteins implicated in cognitive decline. Researchers tested the approach in preclinical models and found promising results in memory function. While early-stage, the findings suggest copper delivery could become a novel therapeutic strategy for Alzheimer's disease. The research team plans further studies to understand the mechanism and move toward human trials.